CAS 881851-50-9
:Larazotide
Description:
Larazotide, with the CAS number 881851-50-9, is a synthetic peptide that has garnered attention for its potential therapeutic applications, particularly in the treatment of celiac disease. It functions primarily as a tight junction regulator, aiming to enhance intestinal barrier function by modulating the permeability of the intestinal epithelium. Larazotide is designed to prevent the passage of gluten peptides across the intestinal barrier, thereby reducing the immune response associated with celiac disease. The substance is typically administered orally and has been evaluated in clinical trials for its efficacy and safety. Its mechanism of action involves the interaction with specific receptors in the gut, which helps to maintain the integrity of the intestinal lining. Larazotide is characterized by its peptide structure, which is crucial for its biological activity. As research continues, the full scope of its pharmacological properties and potential side effects is being explored, contributing to the understanding of its role in gastrointestinal health.
Formula:C34H59N9O12
Synonyms:- Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine
- LARAZOTIDE ACETATE (> 90%)
- H-GLY-GLY-VAL-LEU-VAL-GLN-PRO-GLY-OH
- Larazotide acetate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Larazotide acetate
CAS:Larazotide acetate is a synthetic peptide. It functions as a tight junction regulator and reverses leaky junctions to their normally closed state.Formula:C34H59N9O12Purity:95.53% - 99.425%Color and Shape:SolidMolecular weight:785.89Larazotide acetate
CAS:Controlled Product<p>Larazotide acetate is a drug that inhibits the activity of zonulin, a protein found in the intestines and believed to be involved in the regulation of tight junctions between cells. Larazotide acetate has been shown to reduce symptoms and disease activity in patients with inflammatory bowel disease (IBD). In a study involving human proteins, larazotide acetate was found to bind to actin filaments, which may have implications for its pharmacological use. Larazotide acetate has been shown to inhibit protease activity in various non-clinical studies. This drug is being developed as a potential treatment for autoimmune diseases and other inflammatory diseases.</p>Formula:C32H55N9O10•C2H4O2Purity:Min. 95%Molecular weight:785.89 g/mol
